Subscribe to Updates in Legal, Economic & Regulatory Affairs

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG Topic: Food and Drug Administration (FDA)

The Food and Drug Administration (FDA) is a U.S. government agency tasked with ensuring that no adulterated or misbranded foods, drugs, or medical devices enter interstate commerce. It also oversees dietary supplements, biological medical products, blood products, medical devices, radiation-emitting devices, veterinary products, and cosmetics. It is also the agency that governs clinical trials of medications.

Request a consultation







Leading Experts: Food and Drug Administration (FDA)

What is a GLG Leader?
Jim Farley, President, Cardinal Consulting and TrainingJim Farley
President
Cardinal Consulting and Training

Jim Farley is an Independent Consultant and Owner of Cardinal Consulting and Training. Formerly, Mr. Farley served as the Director of the Science Branch of Philadelphia District FDA. He has over 30 years of experience in pharmaceutical and pharmaceutical packaging industries with extensive experience...

James O'Reilly
Volunteer Professor of Law
University of Cincinnati - CC

James O'Reilly is Volunteer Professor of Law at University of Cincinnati, where he has counseled large and small drug, biotech, device and food firms since becoming a full time professor in 1998. Prof. O’Reilly’s 31 books and 137 articles have been widely cited, and as an FDA expert over many years...

Marc Scheineson, Partner & Chair, Food and Drug Practice, ALSTON & BIRD LLPMarc Scheineson
Partner & Chair, Food and Drug Practice
ALSTON & BIRD LLP

Marc Scheineson is a Partner with Alston & Bird where he heads the firm's Food and Drug Law Practice. He has practiced food and drug law, health care law and administrative law for over 20 years in national law firms and at the FDA. His practice focuses on determining the regulatory course of least...

Tim Gallagher, RPh, Executive Vice President of Pharmacy Operations , ASTRUP DRUG, INC.Tim Gallagher, RPh
Executive Vice President of Pharmacy Operations
ASTRUP DRUG, INC.

Tim Gallagher, RPh, is the Executive Vice President of Pharmacy Operations at Astrup Drug, Inc. Minnesota. He manages all aspects of pharmacy operations for the company. Mr. Gallagher has been a practicing Pharmacist for over 20 years in both the chain and independent community pharmacy setting. He...

Keith Berman, MPH, MBA, Founder, Health Research Associates Keith Berman, MPH, MBA
Founder
Health Research Associates

Keith Berman, MPH, MBA, is the Founder of Health Research Associates. He provides reimbursement consulting, market research and new business planning services to the biomedical products industry. Mr. Berman's technology focus includes biopharmaceuticals, medical devices, and human blood-derived products....

View All GLG Leaders in Legal, Economic & Regulatory Affairs

GLG NewsSM Analysis: Food and Drug Administration (FDA)(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Another New FDA Indication For Abilify | 03-19-2008
Author: GLG Expert Contributor

The FDA’s approval of Abilify for treatment of acute manic and mixed episodes of pediatric Bipolar Disorder is a very important milestone.   Treatment with Abilify already has had growing off-label use in the pediatric population, in both acute and chronic settings, because of its favorable...

Expect speeder FDA reviews in a year maybe. | 05-01-2008
Author: GLG Expert Contributor

In this publications there is am implication that the FDA will approve things faster as the FDA will after hiring so many people with fancy science backgrounds.  This might be true but it probably won't be the case.

Patients and Drug Companies Are Dying for F.D.A. Reform | 04-11-2008
Analysis of: It's Time to Reform the F.D.A. | www.nytimes.com
Author: GLG Expert Contributor

The F.D.A. is the nation's most ubiquitous regulatory agency; every American encounters F.D.A.-regulated products many times every day.  Fulfilling a "gatekeeper" function -- which means that regulators must approve drugs, biologics and medical devices before they can be marketed -- the agency's...

FDA Explodes ZymoGenetics' Recothrom Safety Argument | 05-09-2008
Analysis of: FDA Asks ZymoGenetics to Revise New Product's Press Release | seattletimes.nwsource.com
Author: Keith Berman, MPH, MBA, Founder, Health Research Associates

The FDA -- likely with encouragement of King Pharmaceuticals -- has ordered ZymoGenetics to cease dissemination of materials that cite "a significantly lower incidence of antibody formation compared to the commercially available bovine thrombin product [Thrombin-JMI]." "This statement is false or misleading...

FDA Analysis of Singulair- Wait until the evidence is in. | 04-14-2008
Analysis of: FDA investigates suicide with Merck drug | www.physorg.com
Author: GLG Expert Contributor

The FDA is investigating Merck's Singulair for a possible link to suicidal thought and action.  With over 28 million prescriptions last year and a 12 year record of safety in children and adults, the evidence must be evaluated closely before coming to any conclusion. Of note antihistamines, including...

View All GLG News in Legal, Economic & Regulatory Affairs

GLG InstituteSM Seminars: Food and Drug Administration (FDA)(?)

 
Recent Seminars
GLGi: Cosmetic Dermatology
New York, 02-28-2008
View All View all GLG InstituteSM Seminars in in Legal, Economic & Regulatory Affairs

Quick Facts about GLG

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics